Merck & Co
$526M 13F equity value
14 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Merck & Co covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PSNL | PERSONALIS INC | 14,044,943 | $188M | 35.8% |
| MRNA | MODERNA INC | 2,308,190 | $162M | 30.7% |
| KYMR | KYMERA THERAPEUTICS INC | 772,165 | $89M | 16.8% |
| AKTS | AKTIS ONCOLOGY INC | 952,844 | $31M | 5.8% |
| EIKN | EIKON THERAPEUTICS INC | 1,666,666 | $22M | 4.1% |
| TRDA | ENTRADA THERAPEUTICS INC | 1,739,768 | $13M | 2.4% |
| STRO | SUTRO BIOPHARMA INC | 272,351 | $9M | 1.7% |
| ALEC | ALECTOR INC | 3,545,719 | $7M | 1.4% |
| EVAX | EVAXION BIOTECH A/S | 1,214,126 | $4M | 0.7% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 93,414 | $2M | 0.3% |
Track Merck & Co's 13F portfolio: $526M in reported holdings, 14 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}